|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
The changes in mRNA levels associated with transformation and tumorigenesis as a result of FGF19 administration were also evaluated.
|
21109934 |
2011 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We show that the hepatocyte-specific deletion of Stat3, genetic ablation of Il6, treatment with a neutralizing anti-IL-6 antibody or administration of a small-molecule JAK inhibitor, abolishes FGF19-induced tumorigenesis, while the regulatory functions of FGF19 in bile acid, glucose and energy metabolism remain intact.
|
28508871 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor 4 (FGFR4) has been confirmed to be associated with the progression and prognosis of ovarian cancer, while the underlying mechanism has not been well elucidated and the clinical significance of its ligand, fibroblast growth factor 19 (FGF19), has not been explored.
|
26323668 |
2015 |
|
Carcinoma, Transitional Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the receiver operating characteristic (ROC) curve analysis, FGF19, 21, and 23 were all significant predictors of UC [area under the curve (AUC)] 0.674, P = 0.015; AUC 0.918, P < 0.001; AUC 0.897, P < 0.001, respectively).
|
30334297 |
2019 |
|
Cerebrovascular accident
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This view is consistent with known physiological role of ACOX1 in yielding precursors of specialized proresolving mediators (SPM) and with characteristics of aging and related disorders including reduced PGC1-<i>α</i> function and improvement by strategies rising ACOX1 (via hormonal gut FGF19 and nordihydroguaiaretic acid in metabolic syndrome and diabetes conditions) and SPM (neurodegenerative disorders, atherosclerosis, and stroke).
|
29765501 |
2018 |
|
Childhood Hepatocellular Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
|
31409633 |
2019 |
|
Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
FGF19 has been shown to be involved in EMT in cholangiocarcinoma and colorectal cancer, however, molecular mechanisms underlying FGF19-induced EMT process in hepatocellular carcinoma (HCC) remain largely unknown.
|
26498355 |
2016 |
|
Cholecystolithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In accordance with its murine homolog FGF15, FGF19 might trigger relaxation and filling of the gallbladder which, in combination with increased cholesterol saturation and BA hydrophobicity, would enhance the risk of gallstone development.
|
31254596 |
2019 |
|
Cholelithiasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In accordance with its murine homolog FGF15, FGF19 might trigger relaxation and filling of the gallbladder which, in combination with increased cholesterol saturation and BA hydrophobicity, would enhance the risk of gallstone development.
|
31254596 |
2019 |
|
Cholestasis
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Correspondingly, the serum FGF19 levels decreased significantly in patients with cholestasis.
|
30504803 |
2018 |
|
Cholestasis
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Here we analyzed hepatic expression of FGF19 and other genes relevant to the adaptive response to cholestasis in tissues from non-cirrhotic (n = 24) and cirrhotic (n = 21) patients along with control tissues (n = 21).
|
26293907 |
2015 |
|
Cholestasis
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Levels of fibroblast growth factor 19 (FGF19, FGF15 in rodents) were also increased in liver tissues from patients and rodents with cholestasis.
|
30063921 |
2018 |
|
Cholestasis
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
However, the recent identification of a new type of genetic progressive familial intrahepatic cholestasis (PFIC) linked to FXR mutations has strengthen also the bona fide beneficial effects of target therapies that by-pass FXR activation, directly promoting the action of its target, namely the enterokine FGF19, in the repression of hepatic BAs synthesis with reduction of total BA levels in the liver and serum, accomplishing one of the major goals in cholestasis.
|
28965883 |
2018 |
|
Cholestasis
|
0.070 |
Biomarker
|
disease |
BEFREE |
In this context, therapeutic approaches including the use of new hydrophilic BA such as the conjugation-resistant nor- ursodeoxycholic acid, nuclear receptor (FXR, PPAR-alpha) agonists, FGF19 analogues, inhibitors of the apical sodium-depend bile acid transporter (ASBT) and modulators of the inflammatory cascade triggered by BA are being studied as novel treatments of cholestasis.
|
31196636 |
2017 |
|
Cholestasis
|
0.070 |
Biomarker
|
disease |
BEFREE |
FGF19-based drugs reduce steatosis in patients with NASH, and ameliorate bile acid-induced liver damage in patients with cholestasis.
|
30893110 |
2019 |
|
Cholestasis
|
0.070 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate that the regulation of BA synthesis in response to cholestasis is primarily controlled by circulating FGF19 and that under cholestatic conditions, the FGF19-BA synthesis feedback mechanism remains intact.
|
28570655 |
2017 |
|
Cholestasis of pregnancy
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, our aim was to investigate the circulating FGF-19 and β-klotho levels in intrahepatic cholestasis of pregnancy (ICP) cases.
|
30697260 |
2019 |
|
Cholestasis of pregnancy
|
0.020 |
Biomarker
|
disease |
BEFREE |
We sought to expand our knowledge of the detailed genetic contribution to ICP by investigation of common variation around candidate loci with biological plausibility for a role in ICP (ABCB4, ABCB11, ABCC2, ATP8B1, NR1H4, and FGF19).
|
24366234 |
2014 |
|
Cholestasis, chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Associations of plasma CIT and FGF19 with chronic cholestasis and survival were estimated by logistic and Cox regression models.
|
31075790 |
2019 |
|
Cholestasis, progressive familial intrahepatic 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the recent identification of a new type of genetic progressive familial intrahepatic cholestasis (PFIC) linked to FXR mutations has strengthen also the bona fide beneficial effects of target therapies that by-pass FXR activation, directly promoting the action of its target, namely the enterokine FGF19, in the repression of hepatic BAs synthesis with reduction of total BA levels in the liver and serum, accomplishing one of the major goals in cholestasis.
|
28965883 |
2018 |
|
Cholestatic liver disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the gut-liver axis is not upregulated in preterm and term infants and that neonates with cholestatic liver disease will unlikely benefit from supplemental FGF19.
|
30122083 |
2020 |
|
Chronic intestinal failure
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate whether citrulline (CIT) and the enterokine fibroblast growth factor 19 (FGF19) are associated with chronic cholestasis and survival in adult CIF patients, and to develop a risk score to predict their survival.
|
31075790 |
2019 |
|
Chronic Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results suggest that increased concentrations of FGF19 and FGF21 in patients with CKD may be associated with the metabolism of lipids and carbohydrates.
|
31614355 |
2019 |
|
Chronic liver disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results suggest that selectively targeting the FGF19-FGFR4 pathway may offer a tractable approach to improve the treatment of chronic liver disease and cancer.
|
24728076 |
2014 |
|
Cirrhosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
FGF19 amplifications, known to activate Wnt signaling, were mutually exclusive with CTNNB1 and AXIN1 mutations, and significantly associated with cirrhosis (P = 0.017).
|
24798001 |
2014 |